Peer-reviewed veterinary case report
New chemo combo with lipid nanoemulsion for treating dog lymphoma
By Lucas, S R R et al.·Published in Veterinary and comparative oncology·2015·Department of Internal Medicine, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Pilot clinical study of carmustine associated with a lipid nanoemulsion in combination with vincristine and prednisone for the treatment of canine lymphoma.
- Species:
- dog
Plain-English summary
A group of dogs with lymphoma were treated with a new formulation of carmustine (a chemotherapy drug) combined with vincristine and prednisone, using a lipid nanoemulsion to help deliver the medication. This treatment was compared to a standard carmustine formulation. Both groups of dogs achieved similar results, with some going into complete remission and others showing partial remission. The dogs experienced some low white blood cell counts, but no serious side effects were noted. Overall, the new treatment was found to be safe and effective, suggesting it could be a good option for treating lymphoma in dogs.
People also search for: dog lymphoma treatment · carmustine for dogs · lymphoma in dogs prognosis
Abstract
A lipid nanoemulsion (LDE) resembling low-density lipoprotein can target malignant tumours. In in vivo and clinical studies, association of chemotherapeutic agents to LDE decreased their toxicity and increased pharmacological action. Here, safety of LDE as carmustine carrier (50 mg m(-2) , intravenous) combined with vincristine and prednisone for the treatment of dogs with lymphoma was tested and compared with commercial carmustine with vincristine and prednisone. In five dogs from LDE-carmustine and six from commercial carmustine, complete remission was achieved (P > 0.05). Partial remission occurred in two dogs from each group. In both groups, the median progression-free intervals (119 and 199 days) and overall survival times (207 and 247 days) were equal. Neutropenia was observed in both groups, but no other major toxicities occurred. Therefore, no difference was observed between the treatments. LDE-carmustine was shown to be safe and effective in a drug combination protocol, which encourages larger studies to investigate the use of this novel formulation to treat canine lymphomas.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23615221/